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Genome Research and Traditional
Intellectual Property Protection - A Bad Fit?
Kate H. Murashige*
Introduction
Classic forms of intellectual property include patents, trademarks,
copyrights and trade secrets. Of these, trademarks are of no particular
relevance with regard to genome research in that products such as
Amgen's erythropoietin or Genentech's human growth hormone pose
essentially the same issues as does any commercial product. 1
Likewise, trade secret protection raises the issues that arise in any
context - even if the relatively recent origins of this technology in
academia may create a public relations overlay absent elsewhere. Also,
while copyright protection for DNA sequences has been suggested, it
has generally been considered inappropriate. 2 This leaves patents as
the only mechanism seriously considered by the community involved in
genome research.3
Patents: Some Pros and Cons
Patents are often thought of in terms of holders' ability to exclude
others from marketing a particular product or using a particular process,
thus giving patent holders an opportunity to charge higher prices or to
undermine competition. However, the ultimate purpose of the system
* Dr. Murashige is a partner in Morrison & Foerster, Washington, DC. She
received her B.A. (Chemistry) from Washington University, her Ph.D. (Chemistry)
, from the University of California, Los Angeles, and her J.D. from the University of
Santa Clara.
1 Another form of protection for biotechnology products is Orphan Drug status,
but this, too, presents only problems, and there are many, similar to those
encountered with respect to small molecule pharmaceuticals.
2 Copyright protection is inadequate for two reasons. First, a nucleotide sequence,
which a ppears to be simply a compilation of data is not protectable by copyright; Feist
v. Rural Telephone Service, Inc., 111 S. Ct. 1282 (1991). Second, a copyright does
not protect against independent retrieval of the gene and sequencing.
3 For further discussion of options other than patents, see, e.g., Kate H.
Murashige, Overview of Potential Intellectual Property Protection for Biotechnology,
5 Risk 119 (1994).
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is seen today as attracting private investment in research and
development. It seems to be successful in doing so. In 1994, of the
$182 billion spent on research, the private sector contributed 59%,
whereas the federal government and non-profits, including colleges and
universities, contributed 36% and 5%, respectively.
In 1995, the biotech industry spent $7.7 billion on research and
development. Per employee, the highest spender was Biogen
($210,724), followed by Genetics Institute ($114,943) and Genentech
($112,030). The biotech average was $71,000 - compared to the U.S.
corporate average of $7,650 per employee.
Unlike the situation in 1783, when our patent system was founded,
most progress is not made by individual inventors working alone.
Particularly in the biotech industry; it is made by organized
establishments with laboratories, equipment and technicians. And this
would not happen absent means to recover private capital investments.
On the downside, intellectual curiosity does not rate highly when
the connection between what might come out of intellectual curiosity
and profit is not readily apparent. Also, the more technologically
advanced and complex any activity is, e.g., even farming, the less it
lends itself to individual or small business, and the more it is forced
into activities that require large organizations. Further, the patent
system discourages short-term dissemination of information.4
The patent system may also challenge morality when it brings into
the commercial arena subject matter that was not quite there before.
Some are offended by the very notion of patenting human genes or
transgenic animals. It is not clear whether their objections reside in the
realization that the availability of patents will result in more research
that is itself objectionable, or whether it is just the idea of life forms
being in the commercial domain - slaughterhouses of course aside.
A final problem I will mention is that genome research, and perhaps
medical research in general, encouraged by patent availability creates a
demand for sometimes expensive services. Health care already
consumes 15% of the gross national product. Since it is possible, e.g., to
assay for a breast cancer predicative form of the BRCA 1 gene, does
society want to make it possible for all women to be tested? If
4 And if it doesn't work properly, it may discourage dissemination of information
over the long-term.
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transplants of organs and tissue from pigs to people becomes viable,
does society really want to pay for all of these transplants?
The Patent System and Genome Research
Assuming that, overall, it is desirable to provide patent protection
for genome research, .the present statutory and administrative
framework seem to provide an incredibly poor fit. Let's consider some
issues that arise.
Patent Protection for Genes per se
35 U.S.C. § 103 requires that an invention not be obvious to one of
ordinary skill in the relevant art. The cameo genomic invention is
cloning a gene that encodes a protein of known function. These were
covered by early patents on, e.g., human growth hormone, insulin, G-
CSF and erythropoietin. The U.S. Court of Appeals for the Federal
Circuit has provided a reasonably bright line test for patentability of
genes over prior art disclosing proteins which they encode: Deuel and
its predecessors hold that the native sequence of the gene could not
have been conceived prior to its actual reduction to practice, and it is,
therefore, not obvious. 5 The Federal Circuit has squarely held that
the fact that techniques for cloning genes based on known proteins
could be applied by those of ordinary skill is irrelevant to a claim to the
gene itself - drawn to a composition of matter which must be
described so as to distinguish it from other compositions. The most
reasonable way to do this is to provide the nucleotide sequence. These
holdings, if maintained, might solve a problem with the current test for
non-obviousness. However, it is reasonably certain, in my view, that this
statement of the law will be dramatically modified.
The root of the problem is that, given an isolated and purified
protein of known function, it might be within ordinary skill to retrieve
the gene encoding that protein. Some genes are retrieved more readily
than others, but I doubt that anyone would argue that the gene could
not be retrieved and sequenced with sufficient time, resources and
effort applied by ordinary practitioners. The nucleotide sequence per
5 In re Deuel, 51 F.3d 1552 (Fed. Cir. 1995). See also, In re Bell, 999 F.2d 781
(Fed. Cir. 1993), Fiers v. Sugano, 984 F.2d 1164; (Fed. Cir. 1993), and Amgen, Inc.
v. Chugai Pharmaceutial Co., 927 F.2d 1200, (Fed. Cir. 1991), cert. den., 502 U.S.
856 (1991).
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se is not obvious, but it may be obvious to extract the relevant DNA
from nature and determine its nucleotide sequence.
Ample case law states that experimentation is not "undue," in the
sense that an obviousness rejection can be overcome, merely because it is
time consuming and laborious - as long as the result is clear. This has
been rephrased as "obvious to try with a reasonable expectation of
success." 6 One can argue that there is a reasonable expectation of
success in cloning a gene and that the sequence is inherent. The U.S.
Patent and Trademark Office (PTO) makes this argument
consistently. Yet, once the gene has been cloned and sequenced, it
would be simple for anyone to pirate its information content, and,
without exclusivity, investors would not support the cost of obtaining
the gene in the first place. 7
Why is it unlikely that Deuel and its predecessors will be
maintained in its present form? First, these are Federal Circuit panel
decisions; such decisions cannot reverse those of the predecessor Court
of Customs and Patent Appeals. Also, it is unclear that these decisions
will bind other panels. The writer of all the opinions was Judge Lourie,
whose background in pharmaceuticals logically led to the rationale that
a method for making an invention is not complete without a concept of
the invention itself. This would certainly be the case for pharmaceutical
molecules that do not exist in nature. Second, the structural elements
seemingly required do not appear to have been imposed on other
molecules that are products of nature. For example, claims to
monoclonal antibodies with respect to a particular antigen do not seem
to require that the amino acid sequence of the immunoglobins be
determined or disclosed. The antibodies can be claimed in entirely
functional terms; this has been the practice of the PTO and the subject
of its Board decisions. 8 However, I am aware of no Federal Circuit
case related to the validity of such claims. Third, the idea that sequence
is required to claim a gene is contrary to European law, where it has
6 The formula for obviousness as "obvious to try with a reasonable expectation of
success" was established In re OFarrell, 853 F.2d 894 (Fed. Cir. 1988).
7 Even if copyright were available, it would be inadequate, see supra note 2.
Commercial value would be intolerably undercut by allowing other to retrieve the
information independently.
8 See, e.g., Ex parte Old, 229 U.S.P.Q. 196 (BPAI 1985).
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been held that a description of the process for preparation of the
hepatitis B surface antigen-encoding gene is sufficient to support a
claim to that gene. 9 Only if the gene is actually claimed in terms of
its sequence is such sequence required.10
Finally, it should be clear that structural features of claimed
molecules that exist in nature are inherent in the molecules. Claims
involving natural products must distinguish over what occurs naturally.
Applicants have been permitted to make this all-important distinction
in the most trivial ways by specifying that claimed DNA molecules be
purified and isolated or, e.g., that they be ligated to nucleotide
sequences with which they do not ordinarily reside. That which has
been made a central feature of claims (the sequence) is not what makes
it new.11
Transgenic Animals
The relatively low rate that patents on such subject matter issue
makes this problem less prominent than otherwise. The rate seems to be
more the result of a PTO policy decision than, necessarily, any lack of
fit with patent requirements. 12 However, the same arguments can be
applied; ways to manipulate the genome of certain animals, at least, are
well known - microinjection of fertilized eggs with the transgene or
transformation of embryonic stem cells and reimplantation into the
blastula. Desirable transgenic animals are often suggested by the art.
Thus, for many transgenic animals, it could appropriately be said that
the invention is obvious to try with a reasonable expectation of success.
Again, there is a need for tremendous investment to produce, e.g., a
desired transgenic mouse and more to prepare transgenic cows. Yet, the
ordinary practitioner knows, at least in theory, how to do it and is likely
to succeed given enough time, effort and money. Again, the question is:
If the cost cannot be recouped because the invention is "obvious" and
unpatentable, who will make the effort?
Expressed Sequence Tags
The challenge to the patent system presented by Venter's and
Adams' work at the National Institutes of Health (NIH) in retrieving
9 Decision T 296/93, Technical Board of Appeal of the European Patent Office.
10 Decision T 886/91, Technical Board of Appeal of the European Patent Office.
11 35 U.S.C. § 101 requires that the claimed subject matter be "new."
12 See, e.g., Brian Cunningham's paper in this issue of Risk.
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several thousand, hitherto undisclosed, nucleotide sequences from
cDNA libraries continues. Although the applications based on that
work have been withdrawn, the PTO reports that, as of June 1996,
approximately 80 applications are pending with thousands of
nucleotide sequences each. Indeed, because of difficulties involved in
evaluating patentability of this large number of sequences, the PTO
estimates that it will take eight years to process these applications. To
publicize the problem and seek solutions, hearings were held in April
1996. Involved commercial organizations offered advice, and the
consensus seems to be that searching and examination could be more
efficient. Nevertheless, single applications claiming several thousand
nucleotide sequences are a new experience for the PTO.
Also, such applications do not fit well within the statute. Here is the
problem: While these sequences seem to be new and presumably not
obvious, their utility is questioned. Although uses for individual
sequences have been proposed, it has been argued that these short
Expressed Sequence Tags (ESTs) do not exhibit the type of utility
contemplated by 35 U.S.C. § 101. Thus, while a claim including, e.g.,
10,000 different, individual ESTs could theoretically be patented, this
is inherently offensive to many. They argue that too much protection is
afforded for too little contribution. Each EST, to be exploited, requires
substantial further effort, and proposed claims presumably would block
those, without licenses, who later make such effort.
Jurisdictions outside the U.S. have taken the approach that each
EST is a separate invention. The PTO could join them. However,
10,000 applications would require an outlay of almost $5 million in
filing fees alone.13
Since patents are particularly problematic for protecting this type of
"cinvention," some companies have sought alternatives. Human Genome
Sciences and its research arm, The Institute for Genomic Research,
offer access to their secret database in return for a "right of first refusal"
to license commercial sequelae. Also, Incyte Pharmaceuticals has made
several deals with pharmaceutical companies in which millions of dollars
have been paid for access to its database. Nevertheless, Merck has
13 Yet, for applicati6ns filed prior to June 7, 1995, when GATT amendments came
into effect, this could offer an advantage. Divisional applications for individual ESTs
might be filed one after another over a considerable period, as interest warranted.
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chosen not to rely on trade secret licenses; it is working with
Washington University to generate a multiplicity of sequences to be
made public.
Processes for Preparing Recombinant Materials
A recent decision by .he Federal Circuit makes it clear that patents
covering processes for making recombinant materials for the production
of proteins may effectively extended to preissuance activities. 14 35
U.S.C. § 271(g) extends infringement to offering to sell, importing or
using the product of a patented process during the term of the process
patent. The Court looked to the legislative history of that section and
found that its drafters intended a process for preparing an expression
vector for the production of a recombinant protein to be considered a
process for production of the protein itself. It, thus, becomes apparent
that, even if a plasmid is constructed prior to the issuance of a patent
covering a process for its construction, using cells transformed with this
expression system to produce a protein and selling it during the term of
the process patent infringes that patent.
This temporal discontinuity is not a problem for traditional
technology because processes usually must be repeated to make
additional product which is fairly immediately sold. However,
expression plasmids, need be made only once; they self-replicate and
can be used again and again. Thus, for example, an expression system
might have been constructed in 1990 and a patent issued on a process
for its construction in 1992. The protein produced by the original
system, even if it were maintained all along, could not be sold after
1992 without infringing the process patent.
Algorithms
Discovering how nature operates often leads to new therapeutic
protocols, diagnostic methods and the like. Also, specific method steps
can be followed in designing compounds for pharmaceutical use. In
many cases, the devised methods are sufficiently complex that it makes
sense to formalize them in a computer-based setting; in others, the steps
may comprise simple deduction.
14 Biotechnology General Corp. v. Genentech, Inc., 38 U.S.P.Q.2d 1321 (Fed. Cir.
1996).
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U.S. Patent 5,463,564 is a good example of how claims can be
obtained for a computer-assisted method to design compounds with
desired physiological properties. In effect, claim 1 is simply directed to
looking at several chemical structures and their structure/activity data
and then picking ones that seem most promising. Since the claim
requires that all of this be "'under computer control," it has apparently
escaped rejection on the basis of being a nonstatutory algorithm.
Recent Federal Circuit decisions have indicated a more liberal
attitude toward algorithms. 15 The PTO has also provided potentially
helpful guidelines for examining "software" inventions. 16 Still, it is
unclear that the need to involve computers should be retained.
Conclusion
In at least the five types of inventions set forth above, all common
to biotechnology, the patent system poses considerable difficulty. It
may be possible for the system to simply "muddle through" as in the
past, fine-tuning the system with ad hoc decisions in individual cases.
Yet, consideration might be given to making statutory changes which
would more directly provide for encouragement of investment in
research and development, even when the goals and means for
obtaining the results of such research and development are obvious to
those of ordinary skill.
15 In re Alappat, 33 F.3d 152 (Fed.Cir. 1994); In re Trovato, 60 F.3d 807 (Fed.Cir.
1995).
16 60 Fed. Reg. 7478 (1996).
